ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00956449
Recruitment Status : Completed
First Posted : August 11, 2009
Last Update Posted : March 28, 2017
Sponsor:
Collaborator:
Novartis Vaccines
Information provided by:
Novartis

Brief Summary:
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HI) at 21 days post immunization in non−elderly and elderly subjects in compliance with the requirements of the current European Union (EU) recommendations for the evaluation of the immunogenicity for a new formulation of a licensed flu vaccine (CPMP/BWP/214/96).

Condition or disease Intervention/treatment Phase
Influenza Seasonal Influenza Biological: Seasonal Influenza Vaccine Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 126 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase II, Single Center, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine [Ph.Eur], Formulation 2009/2010, When Administered to Non-Elderly Adult and Elderly Subjects
Study Start Date : June 2009
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Biological: Seasonal Influenza Vaccine
1 dose of Influenza Vaccine Surface Antigen, Inactivated



Primary Outcome Measures :
  1. Immunogenicity and tolerability of the Flu vaccines is being measured [ Time Frame: 2 - 21 days ]

Secondary Outcome Measures :
  1. To evaluate safety of a single IM (intramuscular) dose of the subunit vaccine of Influenza Vaccine Surface Antigen, Inactivated of Influenza Vaccine [ Time Frame: 21 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects eligible for enrollment into this study are male and female adults who are:

    • ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry;
    • able to comply with all study requirements;
    • in good health as determined by:

      1. medical history,
      2. physical examination,
      3. clinical judgment of the investigator.

Exclusion Criteria:

  • Subjects are not to be enrolled into the study if at least one of the following criteria is fulfilled:

    • They have any serious chronic or acute disease (in the judgment of the investigator) including but not limited to:

      1. Cancer, except for localized skin cancer
      2. Advanced congestive heart failure
      3. Chronic obstructive pulmonary disease (COPD)
      4. Autoimmune disease (including rheumatoid arthritis)
      5. Acute or progressive hepatic disease
      6. Acute or progressive renal disease
      7. Severe neurological or psychiatric disorder
      8. Severe Asthma
    • History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to eggs, chicken protein, chicken feathers, influenza viral protein neomycin or polymyxin).
    • Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting for example from:

      1. receipt of immunosuppressive therapy (any parental or oral cortical steroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study;
      2. Receipt of immunostimulants,
      3. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study,
      4. Suspected or known HIV infection or HIV-related disease.
    • Known or suspected history of drug or alcohol abuse.
    • They have a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;
    • Women who are pregnant or woman of childbearing potential unwilling to practice acceptable contraception for the duration of the study (21 days). Females who are pregnant or nursing (breastfeeding) mothers or females of childbearing age who do not plan to use acceptable birth control measures, for the duration of the study. Adequate contraception is defined as hormonal (oral, injection, transdermal patch, implant, cervical ring), barrier (condom or diaphragm), intrauterine device (IUD) or monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject's study entry.
    • Influenza vaccination or laboratory confirmed influenza within the last 6 months and more than one influenza vaccination within the past 12 months
    • Within the past 4 weeks they have received: another vaccine or any investigational agent.
    • Any acute or chronic infection requiring systemic antibiotic treatment or antiviral therapy within the last 7 days.
    • They have experienced fever (i.e., axillary temperature ≥ 38°C) within the last 3 days
    • Simultaneous participation in another clinical study.
    • Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives.
    • Severely obese with Body Mass Index (BMI) > 35
    • Site personnel involved in evaluation of safety and their immediate relatives are excluded from participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00956449


Locations
United Kingdom
The Health Centre
Suffolk, United Kingdom, IP309QU
Sponsors and Collaborators
Novartis
Novartis Vaccines
Investigators
Study Chair: Novartis Vaccines Novartis Vaccines

Additional Information:
Responsible Party: Novartis, Novartis Vaccines
ClinicalTrials.gov Identifier: NCT00956449     History of Changes
Other Study ID Numbers: V78_07S
2009-011004-33
First Posted: August 11, 2009    Key Record Dates
Last Update Posted: March 28, 2017
Last Verified: March 2017

Keywords provided by Novartis:
flu
influenza
seasonal influenza
influenza vaccine antigen
immunogenicity
safety
tolerability
antibody response
intra muscular
elderly
non-elderly

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs